Hebing Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hebing Zhou has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Juan Zhang
Department of Hematology, Beijing Luhe Hospital, Capital Medical University
6 shared publicationsYue Zhang
Department of Hematology, The Affiliated Beijing Luhe Hospital of Capital Medical University, Beijing 101149, P.R. China
5 shared publicationsDanyang Zhang
Department of Hematology, Beijing Luhe Hospital, Capital Medical University
4 shared publicationsHui Zeng
Department of Hematology, Beijing Luhe Hospital, Capital Medical University, Beijing 101100, P.R. China
4 shared publicationsTingting Chen
Department of Hematology, The Affiliated Beijing Luhe Hospital of Capital Medical University, Beijing 101149, P.R. China
4 shared publicationsXiaolei Chen
Department of Hematology, Beijing Luhe Hospital, Capital Medical University
4 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1954192
Case Report: Modified transplantation for a unilobed patient with chronic myeloid leukemia
Although the use of tyrosine kinase inhibitors (TKI) for BCR::ABL in patients with chronic myeloid leukemia (CML) has significantly improved long -term life expectancy, the prognosis for patients with TKI resistance or for those who present with advanced disease is still dismal. As reported in numerous studies, the incidence of CML is higher in males than in females; however, the significant difference has not been observed with respect to age. CML consists of three clinical phases. The first stage is the chronic phase, and the second is accelerated phase, which usually lasts about 3 years; approximately 10% of cases in these two phases progress to the third phase (blastic phase). Allogeneic hematopoietic stem-cell transplantation remains the only curative option for patients with advanced CML. Here, we report a rare case of a 55-year-old female patient with CML who achieved successful outcomes following a lobectomy necessitated by a mucor infection. She experienced an early relapse in the central nervous system (CNS), and prompting a switch in treatment to a different TKI, intrathecal chemotherapy, craniospinal irradiation, and a combination regimen, including azacitidine, venetoclax and cytarabine. The patient presented with early-phase CNS-involved CML during TKI treatment, and subsequently received a transplant from a matched sibling donor using our modified conditioning regimen. This approach was appropriate for the patient. In this case of refractory and relapsed CML complicated by extramedullary involvement, particularly following pathological confirmation after pulmonary lobectomy, we adopted a modified conditioning regimen, which ultimately saved the patient’s life. This strategy serves as a reference for therapeutic approaches for future cases with extremely poor prognosis.
- 6 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1954192
Open AccessCase Report: Modified transplantation for a unilobed patient with chronic myeloid leukemia
Although the use of tyrosine kinase inhibitors (TKI) for BCR::ABL in patients with chronic myeloid leukemia (CML) has significantly improved long -term life expectancy, the prognosis for patients with TKI resistance or for those who present with advanced disease is still dismal. As reported in numerous studies, the incidence of CML is higher in males than in females; however, the significant difference has not been observed with respect to age. CML consists of three clinical phases. The first stage is the chronic phase, and the second is accelerated phase, which usually lasts about 3 years; approximately 10% of cases in these two phases progress to the third phase (blastic phase). Allogeneic hematopoietic stem-cell transplantation remains the only curative option for patients with advanced CML. Here, we report a rare case of a 55-year-old female patient with CML who achieved successful outcomes following a lobectomy necessitated by a mucor infection. She experienced an early relapse in the central nervous system (CNS), and prompting a switch in treatment to a different TKI, intrathecal chemotherapy, craniospinal irradiation, and a combination regimen, including azacitidine, venetoclax and cytarabine. The patient presented with early-phase CNS-involved CML during TKI treatment, and subsequently received a transplant from a matched sibling donor using our modified conditioning regimen. This approach was appropriate for the patient. In this case of refractory and relapsed CML complicated by extramedullary involvement, particularly following pathological confirmation after pulmonary lobectomy, we adopted a modified conditioning regimen, which ultimately saved the patient’s life. This strategy serves as a reference for therapeutic approaches for future cases with extremely poor prognosis.
- Open Access
- 29 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1845797
Case Report: Novel CXCR2 compound heterozygous variants in an infant with neutropenia
Congenital neutropenia refers to a group of rare inherited disorders in which neutrophil development or release is disrupted, predisposing affected children to frequent infections. Among the genes involved, CXCR2 loss-of-function variants have recently been recognized as a distinct cause of the disease. Here, we report a 12-month-old Chinese boy, who presented with repeated febrile respiratory illnesses and intermittent neutropenia since the age of 10 months. During each episode of the child’s viral infection, absolute neutrophil counts ranged between 0.13 and 0.44 ×10 9 /L, while hemoglobin and platelet values remained within the expected range. Lymphocyte subsets and immunoglobulin levels were normal. Whole-exome sequencing revealed two novel CXCR2 variants: a frameshift mutation (c.665delT, p.Val222GlyfsTer4) from his mother and a missense mutation (c.748A>C, p.Met250Leu) from his father. He required intermittent courses of granulocyte colony-stimulating factor and broad-spectrum antibiotics during neutropenic fever episodes. This case expands the mutational and phenotypic spectrum of CXCR2 -related congenital neutropenia and highlights the value of genetic testing for infants with unexplained chronic neutropenia and recurrent infections.
- 29 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1845797
Open AccessCase Report: Novel CXCR2 compound heterozygous variants in an infant with neutropenia
Congenital neutropenia refers to a group of rare inherited disorders in which neutrophil development or release is disrupted, predisposing affected children to frequent infections. Among the genes involved, CXCR2 loss-of-function variants have recently been recognized as a distinct cause of the disease. Here, we report a 12-month-old Chinese boy, who presented with repeated febrile respiratory illnesses and intermittent neutropenia since the age of 10 months. During each episode of the child’s viral infection, absolute neutrophil counts ranged between 0.13 and 0.44 ×10 9 /L, while hemoglobin and platelet values remained within the expected range. Lymphocyte subsets and immunoglobulin levels were normal. Whole-exome sequencing revealed two novel CXCR2 variants: a frameshift mutation (c.665delT, p.Val222GlyfsTer4) from his mother and a missense mutation (c.748A>C, p.Met250Leu) from his father. He required intermittent courses of granulocyte colony-stimulating factor and broad-spectrum antibiotics during neutropenic fever episodes. This case expands the mutational and phenotypic spectrum of CXCR2 -related congenital neutropenia and highlights the value of genetic testing for infants with unexplained chronic neutropenia and recurrent infections.
- Open Access
- 10 November 2025
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 31 (1) , 1-9
Venetoclax combined with azacitidine for treatment of a blastic plasmacytoid dendritic cell neoplasm: A case report and literature review
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematological malignancy. The neoplasm is associated with a poor prognosis and frequent diagnostic challenges, mainly due to its cutaneous manifestations that can delay an accurate diagnosis or lead to its misclassification as other hematological disorders. In the absence of standardized protocols, the management of BPDCN relies on crucial judgment based on individual cases. The present study reports the case of a 51‑year‑old male with BPDCN who presented with a fever and bilateral limb pain, and achieved complete remission after only one cycle of azacitidine‑venetoclax (VA) therapy. As the patient required concurrent administration of posaconazole (a potent CYP3A4 inhibitor), the dose of venetoclax was adjusted to a low dose of 200 mg per day, and the patient still achieved successful disease remission. The findings from this case study highlight the potential of VA therapy in the management of BPDCN. The study also emphasizes the diversity of the clinical manifestations of BPDCN and the crucial role of combination therapy in its management.
- 10 November 2025
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 31 (1) , 1-9
Open AccessVenetoclax combined with azacitidine for treatment of a blastic plasmacytoid dendritic cell neoplasm: A case report and literature review
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematological malignancy. The neoplasm is associated with a poor prognosis and frequent diagnostic challenges, mainly due to its cutaneous manifestations that can delay an accurate diagnosis or lead to its misclassification as other hematological disorders. In the absence of standardized protocols, the management of BPDCN relies on crucial judgment based on individual cases. The present study reports the case of a 51‑year‑old male with BPDCN who presented with a fever and bilateral limb pain, and achieved complete remission after only one cycle of azacitidine‑venetoclax (VA) therapy. As the patient required concurrent administration of posaconazole (a potent CYP3A4 inhibitor), the dose of venetoclax was adjusted to a low dose of 200 mg per day, and the patient still achieved successful disease remission. The findings from this case study highlight the potential of VA therapy in the management of BPDCN. The study also emphasizes the diversity of the clinical manifestations of BPDCN and the crucial role of combination therapy in its management.
- Open Access
- 28 April 2025
- Published by Spandidos Publications in Oncology Letters
- Vol. 29 (6) , 1-8
Azacitidine plus venetoclax for maintenance treatment in intermediate‑to‑low‑risk acute myeloid leukemia: A comparative analysis of clinical outcomes in an observational cohort
The combination of azacitidine (AZA) and venetoclax (VEN) for maintenance treatment in patients with intermediate‑to‑low‑risk acute myeloid leukemia (AML) is a contentious issue. The aim of the present study was to investigate the relationship between the use of VEN plus AZA (VEN‑AZA) and the relapse rate of intermediate‑to‑low‑risk AML among adult Chinese participants. The primary endpoint was AML relapse, analyzed using time‑to‑event methods. A multivariate Cox proportional hazards model was used to compare outcomes between patients who continued VEN‑AZA for maintenance treatment and those who discontinued such therapy. Among the 43 patients, 22 (51.1%) received VEN‑AZA with treatment cycles every 2‑3 months, while the remaining 21 patients discontinued maintenance therapy. The median ages for the two groups were 59 and 49 years, respectively, with an age range of 21‑81 years. With a median follow‑up of 29.6 months (range 7‑74), the median progression‑free survival (PFS) was not reached in the maintenance therapy group and was 47.3 months in the group that discontinued treatment. The number of grade 3‑4 adverse events was low in the maintenance group, with neutropenia and thrombocytopenia as the primary hematological adverse events, and respiratory infection as the main non‑hematological adverse event. Univariate analysis indicated that age, white blood cell count and maintenance therapy were associated with AML relapse. After adjusting for confounding factors, multivariate Cox proportional hazards model showed that maintenance treatment was associated with a reduced risk of relapse and a longer PFS time, compared with discontinued treatment (hazard ratio, 0.06; 95% confidence interval, 0‑0.77). Therefore, patients treated with VEN‑AZA exhibited a longer PFS time, suggesting that further clinical trials are warranted.
- 28 April 2025
- Published by Spandidos Publications in Oncology Letters
- Vol. 29 (6) , 1-8
Open AccessAzacitidine plus venetoclax for maintenance treatment in intermediate‑to‑low‑risk acute myeloid leukemia: A comparative analysis of clinical outcomes in an observational cohort
The combination of azacitidine (AZA) and venetoclax (VEN) for maintenance treatment in patients with intermediate‑to‑low‑risk acute myeloid leukemia (AML) is a contentious issue. The aim of the present study was to investigate the relationship between the use of VEN plus AZA (VEN‑AZA) and the relapse rate of intermediate‑to‑low‑risk AML among adult Chinese participants. The primary endpoint was AML relapse, analyzed using time‑to‑event methods. A multivariate Cox proportional hazards model was used to compare outcomes between patients who continued VEN‑AZA for maintenance treatment and those who discontinued such therapy. Among the 43 patients, 22 (51.1%) received VEN‑AZA with treatment cycles every 2‑3 months, while the remaining 21 patients discontinued maintenance therapy. The median ages for the two groups were 59 and 49 years, respectively, with an age range of 21‑81 years. With a median follow‑up of 29.6 months (range 7‑74), the median progression‑free survival (PFS) was not reached in the maintenance therapy group and was 47.3 months in the group that discontinued treatment. The number of grade 3‑4 adverse events was low in the maintenance group, with neutropenia and thrombocytopenia as the primary hematological adverse events, and respiratory infection as the main non‑hematological adverse event. Univariate analysis indicated that age, white blood cell count and maintenance therapy were associated with AML relapse. After adjusting for confounding factors, multivariate Cox proportional hazards model showed that maintenance treatment was associated with a reduced risk of relapse and a longer PFS time, compared with discontinued treatment (hazard ratio, 0.06; 95% confidence interval, 0‑0.77). Therefore, patients treated with VEN‑AZA exhibited a longer PFS time, suggesting that further clinical trials are warranted.
- Open Access
- 29 September 2022
- Published by Wiley in Disease Markers
- Vol. 2022, 1-19
Identification of Survival-Related Genes in Acute Myeloid Leukemia (AML) Based on Cytogenetically Normal AML Samples Using Weighted Gene Coexpression Network Analysis
The prognosis of acute myeloid leukemia (AML) remains a challenge. In this study, we applied the weighted gene coexpression network analysis (WGCNA) to find survival-specific genes in AML based on 42 adult CN-AML samples from The Cancer Genome Atlas (TCGA) database. Eighteen hub genes (ABCA13, ANXA3, ARG1, BTNL8, C11orf42, CEACAM1, CEACAM3, CHI3L1, CRISP2, CYP4F3, GPR84, HP, LTF, MMP8, OLR1, PADI2, RGL4, and RILPL1) were found to be related to AML patient survival time. We then compared the hub gene expression levels between AML peripheral blood (PB) samples ( ) and control healthy whole blood samples ( ). Seventeen of the hub genes showed lower expression levels in AML PB samples. The gene expression analysis was also done among AML BM (bone marrow) samples of different stages: diagnosis ( ), posttreatment ( ), and recurrent ( ) stages. The results showed a significant increase of ANXA3, CEACM1, RGL4, RILPL1, and HP in posttreatment samples compared to diagnosis and/or recurrent samples. Transcription factor (TF) prediction of the hub genes suggested LTF as the top hit, overlapping 10 hub genes, while LTF itself is just one of the hub genes. Also, 3671 correlation links were shown between 128 mRNAs and 209 lncRNAs found in survival time-related modules. Generally, we identified candidate mRNA biomarkers based on CN-AML data which can be extensively used in AML prognosis. In addition, we mapped their potential regulatory mechanisms with correlated lncRNAs, providing new insights into potential targets for therapies in AML.
- 29 September 2022
- Published by Wiley in Disease Markers
- Vol. 2022, 1-19
Open AccessIdentification of Survival-Related Genes in Acute Myeloid Leukemia (AML) Based on Cytogenetically Normal AML Samples Using Weighted Gene Coexpression Network Analysis
The prognosis of acute myeloid leukemia (AML) remains a challenge. In this study, we applied the weighted gene coexpression network analysis (WGCNA) to find survival-specific genes in AML based on 42 adult CN-AML samples from The Cancer Genome Atlas (TCGA) database. Eighteen hub genes (ABCA13, ANXA3, ARG1, BTNL8, C11orf42, CEACAM1, CEACAM3, CHI3L1, CRISP2, CYP4F3, GPR84, HP, LTF, MMP8, OLR1, PADI2, RGL4, and RILPL1) were found to be related to AML patient survival time. We then compared the hub gene expression levels between AML peripheral blood (PB) samples ( ) and control healthy whole blood samples ( ). Seventeen of the hub genes showed lower expression levels in AML PB samples. The gene expression analysis was also done among AML BM (bone marrow) samples of different stages: diagnosis ( ), posttreatment ( ), and recurrent ( ) stages. The results showed a significant increase of ANXA3, CEACM1, RGL4, RILPL1, and HP in posttreatment samples compared to diagnosis and/or recurrent samples. Transcription factor (TF) prediction of the hub genes suggested LTF as the top hit, overlapping 10 hub genes, while LTF itself is just one of the hub genes. Also, 3671 correlation links were shown between 128 mRNAs and 209 lncRNAs found in survival time-related modules. Generally, we identified candidate mRNA biomarkers based on CN-AML data which can be extensively used in AML prognosis. In addition, we mapped their potential regulatory mechanisms with correlated lncRNAs, providing new insights into potential targets for therapies in AML.
- Open Access
- 14 January 2022
- Published by Wolters Kluwer Health in Chinese Journal of Hematology
- Vol. 43 (1) , 81
异基因造血干细胞移植后Wernicke脑病1例
- 14 January 2022
- Published by Wolters Kluwer Health in Chinese Journal of Hematology
- Vol. 43 (1) , 81
Open Access异基因造血干细胞移植后Wernicke脑病1例
- 23 October 2020
- Published by Spandidos Publications in Oncology Letters
- Vol. 20 (6) , 1
Immune prognostic risk score model in acute myeloid leukemia with normal karyotype
Acute myeloid leukemia with normal karyotype (NK‑AML) is a group of diseases with high heterogeneity and immunological processes are significantly associated with its initiation and development. The implication of the immunogenomic landscape in the prognosis of patients with NK‑AML has remained largely elusive. In the present study, the expression profiles of immune‑related genes (IRGs) were examined and their association with overall survival (OS) was determined in 60 patients with NK‑AML from The Cancer Genome Atlas dataset and 104 patients from the Gene Expression Omnibus (GEO) dataset no. GSE71014. Univariate Cox regression analysis was used to identify 42 and 203 IRGs in the two respective cohorts, which were significantly associated with OS in NK‑AML. A risk model was constructed based on the regression coefficient and expression values of nine survival‑associated IRGs shared between the two datasets [zinc finger CCCH‑type containing, antiviral 1 like; transferrin receptor; suppressor of cytokine signaling 1; ELAV like RNA binding protein 1; roundabout guidance receptor 3; unc‑93 homolog B1, Toll‑like receptor signaling regulator; protein tyrosine phosphatase non‑receptor type 6; interleukin 2 receptor subunit alpha (IL2RA) and IL3RA]. Using this risk model, patients with NK‑AML may be divided into high‑ and low‑risk groups in prognostic predictions. The area under the receiver operating characteristic curve for predicting OS was 0.793. The prognostic role of this risk model was successfully verified in another independent cohort (GEO dataset no. GSE71014). The prognostic risk score was positively associated with age and fms related receptor tyrosine kinase 3 mutation and correlated with infiltration by T regulatory cells. In conclusion, the results of the present study provided an IRG score model for prognostic stratification of adult patients with NK‑AML, as well as further insight into the implication of IRGs in NK‑AML that may lead to the development of novel immunotherapy approaches for this disease.
- 23 October 2020
- Published by Spandidos Publications in Oncology Letters
- Vol. 20 (6) , 1
Immune prognostic risk score model in acute myeloid leukemia with normal karyotype
Acute myeloid leukemia with normal karyotype (NK‑AML) is a group of diseases with high heterogeneity and immunological processes are significantly associated with its initiation and development. The implication of the immunogenomic landscape in the prognosis of patients with NK‑AML has remained largely elusive. In the present study, the expression profiles of immune‑related genes (IRGs) were examined and their association with overall survival (OS) was determined in 60 patients with NK‑AML from The Cancer Genome Atlas dataset and 104 patients from the Gene Expression Omnibus (GEO) dataset no. GSE71014. Univariate Cox regression analysis was used to identify 42 and 203 IRGs in the two respective cohorts, which were significantly associated with OS in NK‑AML. A risk model was constructed based on the regression coefficient and expression values of nine survival‑associated IRGs shared between the two datasets [zinc finger CCCH‑type containing, antiviral 1 like; transferrin receptor; suppressor of cytokine signaling 1; ELAV like RNA binding protein 1; roundabout guidance receptor 3; unc‑93 homolog B1, Toll‑like receptor signaling regulator; protein tyrosine phosphatase non‑receptor type 6; interleukin 2 receptor subunit alpha (IL2RA) and IL3RA]. Using this risk model, patients with NK‑AML may be divided into high‑ and low‑risk groups in prognostic predictions. The area under the receiver operating characteristic curve for predicting OS was 0.793. The prognostic role of this risk model was successfully verified in another independent cohort (GEO dataset no. GSE71014). The prognostic risk score was positively associated with age and fms related receptor tyrosine kinase 3 mutation and correlated with infiltration by T regulatory cells. In conclusion, the results of the present study provided an IRG score model for prognostic stratification of adult patients with NK‑AML, as well as further insight into the implication of IRGs in NK‑AML that may lead to the development of novel immunotherapy approaches for this disease.
- Open Access
- 18 June 2020
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 20 (3) , 2070-2078
Antiproliferative effects of L‑asparaginase in acute myeloid leukemia
The antitumor enzyme L‑asparaginase (L‑Asp) has commonly been used for the treatment of acute lymphoblastic leukemia. However, the effects of L‑Asp on acute myeloid leukemia (AML) and their underlying mechanisms have not been fully elucidated. In the present study, the effects of L‑Asp on cell proliferation and apoptosis were investigated using the AML cell lines U937, HL‑60 and KG‑1a. The effects of combining L‑Asp with mitoxantrone (MIT) and cytarabine (Ara‑c) were also analyzed. The combination of MIT and Ara‑C is known as MA therapy, and is a widely used therapeutic regimen for the treatment of elderly patients with refractory AML. When applied alone, L‑Asp inhibited cell proliferation and induced apoptosis in each of the cell lines tested. Furthermore, the combined use of L‑Asp with MA therapy further potentiated the inhibition of cell proliferation while increasing the induction of apoptosis. These findings provide evidence for the potential antitumor effect of L‑Asp in AML, and indicate that improved efficacy maybe achieved by combining L‑Asp with MIT and Ara‑c. This combination may provide a promising new therapeutic strategy for the treatment of AML.
- 18 June 2020
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 20 (3) , 2070-2078
Open AccessAntiproliferative effects of L‑asparaginase in acute myeloid leukemia
The antitumor enzyme L‑asparaginase (L‑Asp) has commonly been used for the treatment of acute lymphoblastic leukemia. However, the effects of L‑Asp on acute myeloid leukemia (AML) and their underlying mechanisms have not been fully elucidated. In the present study, the effects of L‑Asp on cell proliferation and apoptosis were investigated using the AML cell lines U937, HL‑60 and KG‑1a. The effects of combining L‑Asp with mitoxantrone (MIT) and cytarabine (Ara‑c) were also analyzed. The combination of MIT and Ara‑C is known as MA therapy, and is a widely used therapeutic regimen for the treatment of elderly patients with refractory AML. When applied alone, L‑Asp inhibited cell proliferation and induced apoptosis in each of the cell lines tested. Furthermore, the combined use of L‑Asp with MA therapy further potentiated the inhibition of cell proliferation while increasing the induction of apoptosis. These findings provide evidence for the potential antitumor effect of L‑Asp in AML, and indicate that improved efficacy maybe achieved by combining L‑Asp with MIT and Ara‑c. This combination may provide a promising new therapeutic strategy for the treatment of AML.
- Open Access
- 8 April 2019
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-10
Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
To establish a nomogram for predicting the overall survival (OS) of patients with newly diagnosed multiple myeloma (MM), 304 patients with newly diagnosed MM were recruited between June 1, 2010, and June 30, 2015, from the Beijing Chaoyang Hospital, Capital Medical University, and randomly divided into training (n=214) and validation (n=90) cohorts. The Kaplan-Meier method and the Cox proportional hazards regression model were used to evaluate the prognostic effects of multiple clinical and laboratory parameters on survival. Significant prognostic factors were combined to build a nomogram. The discriminative ability and predictive accuracy of the nomogram were evaluated using the index of concordance (C-index) and calibration curves and compared with the five staging systems currently used for MM. Multivariate analysis of the training cohort revealed that the age at diagnosis, clonal bone marrow plasma cells, serum lactate dehydrogenase, serumβ2-microglobulin, and del (17p) were independent risk factors for OS and were used to establish the nomogram. The C-index value of the nomogram for predicting OS was 0.749, which was significantly higher than the C-indices of the five most common staging systems currently used for MM. In the validation cohort, the C-index for nomogram-based predictions was 0.711 for OS, and the nomogram discrimination was better than the above mentioned five staging systems (P<0.001). All calibration curves revealed good consistency between predicted and actual survivals. The proposed nomogram is more accurate in predicting the prognoses of patients with newly diagnosed MM.
- 8 April 2019
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-10
Open AccessPrognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
To establish a nomogram for predicting the overall survival (OS) of patients with newly diagnosed multiple myeloma (MM), 304 patients with newly diagnosed MM were recruited between June 1, 2010, and June 30, 2015, from the Beijing Chaoyang Hospital, Capital Medical University, and randomly divided into training (n=214) and validation (n=90) cohorts. The Kaplan-Meier method and the Cox proportional hazards regression model were used to evaluate the prognostic effects of multiple clinical and laboratory parameters on survival. Significant prognostic factors were combined to build a nomogram. The discriminative ability and predictive accuracy of the nomogram were evaluated using the index of concordance (C-index) and calibration curves and compared with the five staging systems currently used for MM. Multivariate analysis of the training cohort revealed that the age at diagnosis, clonal bone marrow plasma cells, serum lactate dehydrogenase, serumβ2-microglobulin, and del (17p) were independent risk factors for OS and were used to establish the nomogram. The C-index value of the nomogram for predicting OS was 0.749, which was significantly higher than the C-indices of the five most common staging systems currently used for MM. In the validation cohort, the C-index for nomogram-based predictions was 0.711 for OS, and the nomogram discrimination was better than the above mentioned five staging systems (P<0.001). All calibration curves revealed good consistency between predicted and actual survivals. The proposed nomogram is more accurate in predicting the prognoses of patients with newly diagnosed MM.
- Open Access
- 26 November 2018
- Published by Wiley in BioMed Research International
- Vol. 2018, 1-8
Peripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma
The survival of individuals with tumors may be predicted by the peripheral blood lymphocyte-to-monocyte ratio (LMR) upon diagnosis in recent studies. For patients with multiple myeloma (MM) in the era of novel agents, the prognostic significance of LMR remains unclear. In this study, the prognostic impact of LMR is evaluated by 285 patients with MM who are treated with proteasome inhibitor and/or immunomodulatory drug. LMR is a proven predictor of survival using the receiver operating characteristic curve, with 4.2 as the cutoff point. Patients with LMR ≤ 4.2 at diagnosis had poorer overall survival (OS) and progression-free survival (PFS) than those with LMR > 4.2. In addition, multivariate analysis showed that LMR less than 4.2 is an independent predictor for the OS (hazard ratio [HR]: 1.703; 95% confidence interval [CI]: 1.020–2.842;P= 0.042) and PFS (HR: 1.831; 95% CI: 1.098–3.053;P= 0.021). According to the test, the LMR at diagnosis, which functions as a simple index reflecting host systemic immunity, can predict clinical outcomes in patients with MM who are treated with new agents.
- 26 November 2018
- Published by Wiley in BioMed Research International
- Vol. 2018, 1-8
Open AccessPeripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma
The survival of individuals with tumors may be predicted by the peripheral blood lymphocyte-to-monocyte ratio (LMR) upon diagnosis in recent studies. For patients with multiple myeloma (MM) in the era of novel agents, the prognostic significance of LMR remains unclear. In this study, the prognostic impact of LMR is evaluated by 285 patients with MM who are treated with proteasome inhibitor and/or immunomodulatory drug. LMR is a proven predictor of survival using the receiver operating characteristic curve, with 4.2 as the cutoff point. Patients with LMR ≤ 4.2 at diagnosis had poorer overall survival (OS) and progression-free survival (PFS) than those with LMR > 4.2. In addition, multivariate analysis showed that LMR less than 4.2 is an independent predictor for the OS (hazard ratio [HR]: 1.703; 95% confidence interval [CI]: 1.020–2.842;P= 0.042) and PFS (HR: 1.831; 95% CI: 1.098–3.053;P= 0.021). According to the test, the LMR at diagnosis, which functions as a simple index reflecting host systemic immunity, can predict clinical outcomes in patients with MM who are treated with new agents.